6CM
ANTX icon

683 Capital Management’s AN2 Therapeutics ANTX Stock Holding History

683 Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,392
Closed -$274K – 146
2023
Q4 		$274K Buy
+13,392
New +$224K 0.02% 133

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

683 Capital Management's ANTX Position: Q1 2024 in Review

683 Capital Management sold out of AN2 Therapeutics (ANTX) in Q1 2024, closing a stake of 13,392 shares — an estimated $274K sold.

683 Capital Management first reported a position in ANTX in Q4 2023 and held it in 1 quarter. The position peaked at $274K in Q4 2023. 54 funds tracked by Wall St. Rank hold ANTX as of Q1 2024.

  • 683 Capital Management reported no remaining AN2 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 13,392 AN2 Therapeutics shares in Q1 2024, an estimated $274K.
  • 683 Capital Management first reported a position in AN2 Therapeutics in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's AN2 Therapeutics position peaked at $274K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.